{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Self-nanoemulsifying drug delivery systems (SNEDDS)", "antioxidant activity", "combined dosage form", "glucose inhibition", "oral bioavailability enhancement", "sitagliptin and dapagliflozin"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "33345632", "DateCompleted": {"Year": "2021", "Month": "09", "Day": "15"}, "DateRevised": {"Year": "2022", "Month": "01", "Day": "08"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1080/10717544.2020.1859001"], "Journal": {"ISSN": "1521-0464", "JournalIssue": {"Volume": "28", "Issue": "1", "PubDate": {"Year": "2021", "Month": "Dec"}}, "Title": "Drug delivery", "ISOAbbreviation": "Drug Deliv"}, "ArticleTitle": "Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus.", "Pagination": {"StartPage": "100", "EndPage": "114", "MedlinePgn": "100-114"}, "Abstract": {"AbstractText": ["Control of hyperglycemia and prevention of glucose reabsorption (glucotoxicity) are important objectives in the management of type 2 diabetes. This study deals with an oral combined dosage form design for two anti-diabetic drugs, sitagliptin and dapagliflozin using self-nanoemulsifying drug delivery systems (SNEDDS). The SNEDDS were developed using naturally obtained bioactive medium-chain/long-chain triglycerides oil, mixed glycerides and nonionic surfactants, and droplet size was measured followed by the test for antioxidant activities. Equilibrium solubility and dynamic dispersion experiments were conducted to achieve the maximum drug loading. The <i>in\u00a0vitro</i> digestion, <i>in\u00a0vivo</i> bioavailability, and anti-diabetic effects were studied to compare the representative SNEDDS with marketed product Dapazin<sup>\u00ae</sup>. The representative SNEDDS containing black seed oil showed excellent self-emulsification performance with transparent appearance. Characterization of the SNEDDS showed nanodroplets of around 50-66.57\u2009nm in size (confirmed by TEM analysis), in addition to the high drug loading capacity without causing any precipitation in the gastro-intestinal tract. The SNEDDS provided higher antioxidant activity compared to the pure drugs. The <i>in\u00a0vivo</i> pharmacokinetic parameters of SNEDDS showed significant increase in <i>C</i> <sub>max</sub> (1.99\u2009\u00b1\u20090.21\u2009\u00b5g\u00a0mL<sup>-1</sup>), AUC (17.94\u2009\u00b1\u20091.25\u2009\u00b5g\u00a0mL<sup>-1</sup>), and oral absorption (2-fold) of dapagliflozin compared to the commercial product in the rat model. The anti-diabetic studies showed the significant inhibition of glucose level in treated diabetic mice by SNEDDS combined dose compared to the single drug therapy. The combined dose of sitagliptin-dapagliflozin using SNEDDS could be a potential oral pharmaceutical product for the improved treatment of type 2 diabetes mellitus."]}, "AuthorList": [{"Identifier": ["0000-0002-5611-0378"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia."}], "LastName": "Kazi", "ForeName": "Mohsin", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia."}], "LastName": "Alqahtani", "ForeName": "Abdulmohsen", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia."}], "LastName": "Ahmad", "ForeName": "Ajaz", "Initials": "A"}, {"Identifier": ["0000-0003-0902-6381"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Aromatic, and Poisonous Plants Research Center, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia."}], "LastName": "Noman", "ForeName": "Omar M", "Initials": "OM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Center, King Fahad Medical City, Riyadh, Saudi Arabia."}], "LastName": "Aldughaim", "ForeName": "Mohammed S", "Initials": "MS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia."}], "LastName": "Alqahtani", "ForeName": "Ali S", "Initials": "AS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia."}], "LastName": "Alanazi", "ForeName": "Fars K", "Initials": "FK"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Drug Deliv", "NlmUniqueID": "9417471", "ISSNLinking": "1071-7544"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Benzhydryl Compounds"}, {"RegistryNumber": "0", "NameOfSubstance": "Drug Combinations"}, {"RegistryNumber": "0", "NameOfSubstance": "Emulsions"}, {"RegistryNumber": "0", "NameOfSubstance": "Glucosides"}, {"RegistryNumber": "0", "NameOfSubstance": "Hypoglycemic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Oils"}, {"RegistryNumber": "1ULL0QJ8UC", "NameOfSubstance": "dapagliflozin"}, {"RegistryNumber": "C2J9B08Q3I", "NameOfSubstance": "caraway oil"}, {"RegistryNumber": "TS63EW8X6F", "NameOfSubstance": "Sitagliptin Phosphate"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Area Under Curve"}, {"QualifierName": ["administration & dosage", "pharmacokinetics"], "DescriptorName": "Benzhydryl Compounds"}, {"QualifierName": [], "DescriptorName": "Chemistry, Pharmaceutical"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Diabetes Mellitus, Experimental"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Diabetes Mellitus, Type 2"}, {"QualifierName": [], "DescriptorName": "Drug Combinations"}, {"QualifierName": [], "DescriptorName": "Drug Liberation"}, {"QualifierName": ["chemistry"], "DescriptorName": "Emulsions"}, {"QualifierName": ["administration & dosage", "pharmacokinetics"], "DescriptorName": "Glucosides"}, {"QualifierName": [], "DescriptorName": "Hypoglycemic Agents"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Metabolic Clearance Rate"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Microscopy, Electron, Transmission"}, {"QualifierName": ["chemistry"], "DescriptorName": "Nanoparticles"}, {"QualifierName": [], "DescriptorName": "Particle Size"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plant Oils"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Wistar"}, {"QualifierName": ["administration & dosage", "pharmacokinetics"], "DescriptorName": "Sitagliptin Phosphate"}, {"QualifierName": [], "DescriptorName": "Solubility"}, {"QualifierName": [], "DescriptorName": "Surface Properties"}], "CoiStatement": "No potential conflict of interest was reported by the author(s)."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Abdelrazek HMA, Kilany OE, Muhammad MAA, et al. (2018). Black seed thymoquinone improved insulin secretion, hepatic glycogen storage, and oxidative stress in streptozotocin-induced diabetic male Wistar rats. Oxid Med Cell Longev 2018:8104165.", "ArticleIdList": ["PMC5857299", "29686746"]}, {"Citation": "Agarwal V, Siddiqui A, Ali H, Nazzal S. (2009). Dissolution and powder flow characterization of solid self-emulsified drug delivery system (SEDDS). Int J Pharm 366:44\u201352.", "ArticleIdList": ["18832019"]}, {"Citation": "Al Dawish MA, Robert AA, Braham R, et al. (2016). Diabetes mellitus in Saudi Arabia: a review of the recent literature. Curr Diabetes Rev 12:359\u201368.", "ArticleIdList": ["26206092"]}, {"Citation": "Al-Faris EA, Amin HS, Al-Rukban MO. (2006). Outpatient management of type 2 diabetic patients: a review of evidence-based literature. J Family Community Med 13:3\u201312.", "ArticleIdList": ["PMC3410075", "23012096"]}, {"Citation": "Ali B, Blunden G. (2003). Pharmacological and toxicological properties of Nigella sativa. Phytother Res 17:299\u2013305.", "ArticleIdList": ["12722128"]}, {"Citation": "Alwadei M, Kazi M, Alanazi FK. (2019). Novel oral dosage regimen based on self-nanoemulsifying drug delivery systems for codelivery of phytochemicals \u2013 Curcumin and thymoquinone. Saudi Pharm J 27:866\u201376.", "ArticleIdList": ["PMC6734017", "31516329"]}, {"Citation": "Aquilante CL, Zhang W, McCollum M. (2007). Race, ethnicity, and use of thiazolidinediones among US adults with diabetes. Curr Med Res Opin 23:489\u201394.", "ArticleIdList": ["17355730"]}, {"Citation": "Atef E, Belmonte AA. (2008). Formulation and in\u00a0vitro and in\u00a0vivo characterization of a phenytoin self-emulsifying drug delivery system (SEDDS). Eur J Pharm Sci 35:257\u201363.", "ArticleIdList": ["18706499"]}, {"Citation": "Brand-Williams W, Cuvelier M-E, Berset C. (1995). Use of a free radical method to evaluate antioxidant activity. LWT-Food Sci Technol 28:25\u201330."}, {"Citation": "Charbonnel B, Karasik A, Liu J, et al. (2006). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29:2638\u201343.", "ArticleIdList": ["17130197"]}, {"Citation": "Charpentier G. (2002). Oral combination therapy for type 2 diabetes. Diabetes Metab Res Rev 18 (Suppl 3):S70\u20136.", "ArticleIdList": ["12324989"]}, {"Citation": "Del Prato S, Nauck M, Duran-Garcia S, et al. (2015). Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab 17:581\u201390.", "ArticleIdList": ["25735400"]}, {"Citation": "Dey J. (2017). SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus. Postgrad Med 129:409\u201320.", "ArticleIdList": ["28322073"]}, {"Citation": "Fioretto P, Avogaro A. (2017). Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opin Pharmacother 18:517\u201327.", "ArticleIdList": ["28277831"]}, {"Citation": "Gallwitz B. (2007). Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes. Drugs Today (Barc) 43:681\u20139.", "ArticleIdList": ["17987221"]}, {"Citation": "Garg V, Kaur P, Singh SK, et al. (2017). Solid self-nanoemulsifying drug delivery systems for oral delivery of polypeptide-k: formulation, optimization, in-vitro and in-vivo antidiabetic evaluation. Eur J Pharm Sci 109:297\u2013315.", "ArticleIdList": ["28842349"]}, {"Citation": "Goreja W. (2003). Black seed: nature\u2019s miracle remedy. Amazing Herbs Press: Karger Publishers."}, {"Citation": "Jabbour SA, Hardy E, Sugg J, Parikh S, Study 10 Group. (2014). Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 37:740\u201350.", "ArticleIdList": ["24144654"]}, {"Citation": "Ji L, Han P, Wang X, et al. (2016). Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus. J Diabetes Investig 7:727\u201336.", "ArticleIdList": ["PMC5009135", "27181998"]}, {"Citation": "Kazi M, Al Amri R, Alanazi FK, Hussain MD. (2018). In vitro methods for in\u00a0vitro-in\u00a0vivo correlation (IVIVC) for poorly water soluble drugs: lipid based formulation perspective. Curr Drug Deliv 15:918\u2013929.", "ArticleIdList": ["29336263"]}, {"Citation": "Kazi M, Al-Amri KA, Alanazi FK. (2017). The role of lipid-based drug delivery systems for enhancing solubility of highly selective antiviral agent acyclovir. Pharm Dev Technol 22:312\u201321.", "ArticleIdList": ["26458371"]}, {"Citation": "Kazi M, Alhajri A, Alshehri SM, et al. (2020). Enhancing oral bioavailability of apigenin using a bioactive self-nanoemulsifying drug delivery system (Bio-SNEDDS): in\u00a0vitro, in\u00a0vivo and stability evaluations. Pharmaceutics 12:749.", "ArticleIdList": ["PMC7465069", "32785007"]}, {"Citation": "Kazi M, Al-Swairi M, Ahmad A, et al. (2019). Evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for poorly water-soluble talinolol: preparation, in\u00a0vitro and in\u00a0vivo assessment. Front Pharmacol 10:459.", "ArticleIdList": ["PMC6507620", "31118895"]}, {"Citation": "Kazi M, Shahba AA, Alrashoud S, Alwadei M, et al. (2020). Bioactive self-nanoemulsifying drug delivery systems (Bio-SNEDDS) for combined oral delivery of curcumin and piperine. Molecules 25:1703.", "ArticleIdList": ["PMC7181043", "32276393"]}, {"Citation": "Kazi M, Shariare MH, Al-bgomi M, Hussain MD, et al. (2018). Simultaneous determination of curcumin (Cur) and thymoquinone (THQ) in lipid based self-nanoemulsifying systems and its application to the commercial product using UHPLC-UV-Vis spectrophotometer. CPA 14:277\u201385."}, {"Citation": "Khursheed R, Singh SK, Wadhwa S, et al. (2020). Exploring role of probiotics and Ganoderma lucidum extract powder as solid carriers to solidify liquid self-nanoemulsifying delivery systems loaded with curcumin. Carbohydr Polym 250:116996.", "ArticleIdList": ["33049905"]}, {"Citation": "Kommuru T, Gurley B, Khan M, Reddy I. (2001). Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm 212:233\u201346.", "ArticleIdList": ["11165081"]}, {"Citation": "Lopez AD, Mathers CD. (2006). Measuring the global burden of disease and epidemiological transitions: 2002\u20132030. Ann Trop Med Parasitol 100:481\u201399.", "ArticleIdList": ["16899150"]}, {"Citation": "Mathers CD, Loncar D. (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3:e442.", "ArticleIdList": ["PMC1664601", "17132052"]}, {"Citation": "Miller SA, St Onge EL, Accardi JR. (2009). Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2:23\u201330.", "ArticleIdList": ["PMC3048004", "21437116"]}, {"Citation": "Mohsin K, Alamri R, Ahmad A, et al. (2016). Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug. Int J Nanomedicine 11:2829\u201338.", "ArticleIdList": ["PMC4914069", "27366063"]}, {"Citation": "Mohsin K, Pouton CW. (2012). The influence of the ratio of lipid to surfactant and the presence of cosolvent on phase behaviour during aqueous dilution of lipid-based drug delivery systems. J Drug Deliv Sci Technol 22:531\u201340."}, {"Citation": "Nasr A, Gardouh A, Ghorab M. (2016). Novel solid self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of olmesartan medoxomil: design, formulation, pharmacokinetic and bioavailability evaluation. Pharmaceutics 8:20.", "ArticleIdList": ["PMC5039439", "27355963"]}, {"Citation": "Nichols GA, Koo YH, Shah SN. (2007). Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med 22:453\u20138.", "ArticleIdList": ["PMC1829438", "17372792"]}, {"Citation": "Pandey NK, Singh SK, Gulati M, et al. (2020). Overcoming the dissolution rate, gastrointestinal permeability and oral bioavailability of glimepiride and simvastatin co-delivered in the form of nanosuspension and solid self-nanoemulsifying drug delivery system: a comparative study. J Drug Deliv Sci Technol 60:102083."}, {"Citation": "Plosker GL. (2012). Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 72:2289\u2013312.", "ArticleIdList": ["23170914"]}, {"Citation": "Plosker GL. (2014). Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs 74:223\u201342.", "ArticleIdList": ["24407560"]}, {"Citation": "Pouton CW. (2006). Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 29:278\u201387.", "ArticleIdList": ["16815001"]}, {"Citation": "Q2A I (R1). (2005). Validation of analytical procedures: text and methodology. International Conference on Harmonization, Geneva, Switzerland.\u00a0November, 2005."}, {"Citation": "Salem ML. (2005). Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol 5:1749\u201370.", "ArticleIdList": ["16275613"]}, {"Citation": "Salmani JMM, Asghar S, Lv H, Zhou J. (2014). Aqueous solubility and degradation kinetics of the phytochemical anticancer thymoquinone; probing the effects of solvents, pH and light. Molecules 19:5925\u201339.", "ArticleIdList": ["PMC6270770", "24815311"]}, {"Citation": "Santos LL, Lima FJC, Sousa-Rodrigues CF, Barbosa FT. (2017). Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus. Rev Assoc Med Bras (1992) 63:636\u201341.", "ArticleIdList": ["28977090"]}, {"Citation": "Scheen AJ, Van Gaal LF. (2013). Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation. Rev Med Liege 68:504\u201310.", "ArticleIdList": ["24298724"]}, {"Citation": "Shimoda S, Iwashita S, Ichimori S, et al. (2013). Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. Endocr J 60:1207\u201314.", "ArticleIdList": ["23912974"]}, {"Citation": "Thomas N, Richter K, Pedersen TB, et al. (2014). In vitro lipolysis data does not adequately predict the in\u00a0vivo performance of lipid-based drug delivery systems containing fenofibrate. AAPS J 16:539\u201349.", "ArticleIdList": ["PMC4012058", "24687210"]}, {"Citation": "Vahatalo M, Ronnemaa T, Viikari J. (2007). Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice. Scand J Prim Health Care 25:147\u201353.", "ArticleIdList": ["PMC3379773", "17846932"]}, {"Citation": "Velioglu Y, Mazza G, Gao L, Oomah B. (1998). Antioxidant activity and total phenolics in selected fruits, vegetables, and grain products. J Agric Food Chem 46:4113\u20137."}, {"Citation": "Wilding J, Bailey C, Rigney U, et al. (2017). Dapagliflozin therapy for type 2 diabetes in primary care: changes in HbA1c, weight and blood pressure over 2 years follow-up. Prim Care Diabetes 11:437\u201344.", "ArticleIdList": ["28583425"]}, {"Citation": "Yki-Jarvinen H. (2002). Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 18:S77\u2013S81.", "ArticleIdList": ["12324990"]}, {"Citation": "Zerilli T, Pyon EY. (2007). Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Ther 29:2614\u201334.", "ArticleIdList": ["18201579"]}, {"Citation": "Zhang P, Liu Y, Feng N, Xu J. (2008). Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. Int J Pharm 355:269\u201376.", "ArticleIdList": ["18242895"]}, {"Citation": "Zhang X, Chen G, Zhang T, et al. (2014). Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigation. Int J Nanomedicine 9:5503\u20135514.", "ArticleIdList": ["PMC4251747", "25473287"]}]}], "History": [{"Year": "2020", "Month": "12", "Day": "21", "Hour": "8", "Minute": "42"}, {"Year": "2020", "Month": "12", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "9", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "12", "Day": "21"}], "PublicationStatus": "ppublish", "ArticleIdList": ["33345632", "PMC7875557", "10.1080/10717544.2020.1859001"]}}]}